Table 2.
Comparison of ethnicity, symptom improvement and change in biologic measurements over 8 weeks by treatment arm
| Placebo (n = 13) |
Venlafaxine (n = 9) |
Estradiol (n = 8) |
P valuea | |
|---|---|---|---|---|
| Ethnicity | 0.02 | |||
| Black | 3 (23%) | 3 (33%) | 7 (88%) | |
| Non-black | 8 (77%) | 6 (67%) | 1 (12%) | |
| MBS improved | 7 (54%) | 7 (78%) | 7 (88%) | 0.28 |
|
| ||||
| Median change (IQR) in: | P valueb | |||
|
| ||||
| Glycogen | 0.6 (−3.7, 1.7) | 2.1 (−1.0, 32.7) | 1.2 (−2.5, 4.6) | 0.58 |
| Estradiol (T)c | −4.7 (−12.8, 19.5) | 38 (1.7, 99) | 119 (23, 235) | 0.03 |
| Estradiol (Un) | 1.4 (−2.1, 3.1) | 10 (9, 100) | 58 (4.2, 79) | 0.13 |
| Estrone (T) | 50 (7.8, 220) | 65 (−22, 553) | 616 (578, 1376) | 0.05 |
| Estrone (Un) | 1.8 (−6.3, 5.8) | 11.1 (−10.7, 59.9) | 15.4 (3.5, 66.5) | 0.17 |
a
Fisher’s exact test,
b
Kruskall Wallis
c
Serum estrogen values not available for 6 participants from placebo group, 2 from venlafaxine group and 3 from estradiol group.
MBS = most bothersome symptom, (T) = Total, (Un) = Unconjugated